Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Tirzepatide helps obese adults lose over 15% of body weight in 52 weeks—and retain much of it even six months after stopping ...

Tirzepatide use vs placebo was associated with slower decline in eGFR among patients with prediabetes and obesity or overweight.

Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper understands. A five-year trial of the weight loss drug tirzepatide in ...

Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...

These results were recently published in Nature Medicine in the study titled "Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial." Subscribe to ...

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer and weight-loss therapy.

In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, Chinese obese individuals can maintain significant ...

HealthDay News — For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7% on average, which is lower than the percentages reported ...

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with overweight or obesity compared to use of tirzepatide treatment alone, ...